Use Alkermes Inc. media headlines with your portfolios to protect against small markets fluctuations as well as to determine Stock diversification method that is right for you.
VIVITROL? Data to be Presented at Upcoming American Psychiatric Association ...
EON: Enhanced Online News (press release) - May 4, 2012
DUBLIN--(EON: Enhanced Online News)--Alkermes plc (NASDAQ: ALKS) today announced that data from several company-sponsored studies of naltrexone for extended-release injectable suspension (XR-NTX) are scheduled to be presented at the 2012 American ...
Alkermes' Corporate Presentation to be Webcast at the R.W. Baird Growth Stock ...
MarketWatch (press release) - May 3, 2012
DUBLIN, May 03, 2012 (BUSINESS WIRE) -- Alkermes plc (NASDAQ:ALKS) announced today that its corporate presentation will be webcast live at the RW Baird Growth Stock Conference on Thursday, May 10, 2012, at 12:40 pm CDT (1:40 pm EDT/6) from the Four ...
ALKERMES PLC : VIVITROL? Data to be Presented at Upcoming American Psychiatric ...
4-traders - May 3, 2012
Alkermes plc (NASDAQ: ALKS) today announced that data from several company-sponsored studies of naltrexone for extended-release injectable suspension (XR-NTX) are scheduled to be presented at the 2012 American Psychiatric Association (APA) Annual ...
VIVITROL(R) Data to be Presented at Upcoming American Psychiatric Association ... - MarketWatch (press release)
(RTTNews) - Zogenix, Inc. (ZGNX: News ) said it has submitted a New Drug Application to the US Food and Drug Administration for Zohydro (hydrocodone bitartrate extended-release capsules), Zogenix's lead investigational product candidate for the ...
Investorplace.com - Apr 2, 2012
It looks like Amylin Pharmaceuticals (NASDAQ:AMLN) is finally in play. If the Mar. 28 report from Bloomberg is accurate, Amylin is surely attracting suitors.
Active Stock Alerts: Amylin Pharmaceuticals, Allergan, Tyco International ...
Wall St. Cheat Sheet - Mar 29, 2012
By Derek Hoffman Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN): Baird said a buyout of Amylin (NASDAQ:AMLN) is possible and although not recommending the shares on takeover speculation they do believe it is worth having a position.
Zacks.com - Mar 16, 2012
Elan (ELN) recently announced that it has sold 24.15 million shares, or 76% of its stake in Alkermes plc (ALKS). Excluding underwriter fees, Elan recorded net proceeds of approximately $381 million from this transaction.
The Pharma Letter - Mar 14, 2012
The European Medicines Agency says it has been formally notified by the Irish subsidiary of US drugmaker Alkermes (Nasdaq: ALKS) of its decision to withdraw its application for a centralized marketing authorization for the medicine Megestrol Alkermes ...
MarketWatch (press release) - Mar 13, 2012
DUBLIN, Mar 13, 2012 (BUSINESS WIRE) -- Alkermes plc (NASDAQ:ALKS) ("Alkermes") today announced the completion of an underwritten public offering of 24150000 ordinary shares held by a subsidiary of Elan Corporation, plc ("Elan") at a price to the ...
MarketWatch (press release) - Mar 8, 2012
DUBLIN, Mar 08, 2012 (BUSINESS WIRE) -- Alkermes plc (NASDAQ:ALKS) ("Alkermes") today announced the pricing of an underwritten public offering of 21000000 ordinary shares held by a subsidiary of Elan Corporation, plc ("Elan") at a price to the public ...
Alkermes' Corporate Presentation to be Webcast at the Cowen & Company 32nd ...
Business Wire (press release) - 13 hours ago
DUBLIN--(BUSINESS WIRE)--Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Cowen & Company 32 nd Annual Health Care Conference on Monday, March 5, 2012, at 3:30 pm EST (8:30 pm GMT) from the Boston ...
Based on latest financial disclosure Alkermes Inc. has Total Debt of 444.46 M. This is 64.58% lower than that of Healthcare sector, and 65.52% lower than that of Drug Delivery industry, The Total Debt for all stocks is 90.63% higher than the company.
In most industries, total debt may also include current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meaningful to compare total debt amounts between companies that operate within the same sector.
USA 
Equity Search
Advanced Search
Market Screener
Adviser Directory
Suggest Portfolio
Backtest Watchlist
Analyze Correlations
View Transactions
Check Volatility
Import Equities
Summary
Fundamentals
Technicals
Performance
Valuation
Volatility
History
News
Management
Discussion
